Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric M Ruderman

Showing results (21-30 of 66) with videos related to

Pageof 7
Sort By:
Rheumatic Diseases Clinics of North America|July 18, 2025
Combined Dermatology/Rheumatology Clinics for Management of Psoriatic Disease: Current StateEric M Ruderman, Kenneth B Gordon
Arthritis Research & Therapy|September 1, 2011
More than just B-cell inhibitionEric M Ruderman, Richard M Pope
Bulletin of the NYU Hospital for Joint Diseases|November 1, 2011
Interleukin 6 inhibition - RA and beyondRobert S Woodrick, Eric M Ruderman
Postgraduate Medicine|December 8, 2004
Damage control in rheumatoid arthritis. Hard-hitting, early treatment is crucial to curbing joint destructionSakeba N Issa, Eric M Ruderman
Bulletin of the NYU Hospital for Joint Diseases|December 25, 2012
IL-6 inhibition for the treatment of rheumatoid arthritis and other conditionsRobert S Woodrick, Eric M Ruderman
Arthritis Research & Therapy|April 19, 2005
The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritisEric M Ruderman, Richard M Pope
Journal of the American Academy of Dermatology|February 21, 2006
The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approachKenneth B Gordon, Eric M Ruderman
Nature Clinical Practice. Rheumatology|November 30, 2006
Drug Insight: abatacept for the treatment of rheumatoid arthritisEric M Ruderman, Richard M Pope
Nature Reviews. Rheumatology|October 13, 2011
Safety of biologic therapy in rheumatoid arthritisRobert S Woodrick, Eric M Ruderman
Rheumatic Diseases Clinics of North America|October 18, 2015
Natural History, Prognosis, and Socioeconomic Aspects of Psoriatic ArthritisPhilip S Helliwell, Eric M Ruderman
Pageof 7

Showing results (21-30 of 66) with videos related to

Sort By:
Pageof 7
Rheumatic Diseases Clinics of North America|July 18, 2025
Combined Dermatology/Rheumatology Clinics for Management of Psoriatic Disease: Current StateEric M Ruderman, Kenneth B Gordon
Arthritis Research & Therapy|September 1, 2011
More than just B-cell inhibitionEric M Ruderman, Richard M Pope
Bulletin of the NYU Hospital for Joint Diseases|November 1, 2011
Interleukin 6 inhibition - RA and beyondRobert S Woodrick, Eric M Ruderman
Postgraduate Medicine|December 8, 2004
Damage control in rheumatoid arthritis. Hard-hitting, early treatment is crucial to curbing joint destructionSakeba N Issa, Eric M Ruderman
Bulletin of the NYU Hospital for Joint Diseases|December 25, 2012
IL-6 inhibition for the treatment of rheumatoid arthritis and other conditionsRobert S Woodrick, Eric M Ruderman
Arthritis Research & Therapy|April 19, 2005
The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritisEric M Ruderman, Richard M Pope
Journal of the American Academy of Dermatology|February 21, 2006
The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approachKenneth B Gordon, Eric M Ruderman
Nature Clinical Practice. Rheumatology|November 30, 2006
Drug Insight: abatacept for the treatment of rheumatoid arthritisEric M Ruderman, Richard M Pope
Nature Reviews. Rheumatology|October 13, 2011
Safety of biologic therapy in rheumatoid arthritisRobert S Woodrick, Eric M Ruderman
Rheumatic Diseases Clinics of North America|October 18, 2015
Natural History, Prognosis, and Socioeconomic Aspects of Psoriatic ArthritisPhilip S Helliwell, Eric M Ruderman
Pageof 7